Fentanyl for breakthrough cancer pain - What's new?

Pain

Volumn 151, Issue 3, 2010, Pages 565-566

  Hagelberg, Nora M ^a   Olkkola, Klaus T ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

FENTANYL; MORPHINE; OXYCODONE;

ANALGESIA; CANCER PAIN; CANCER PATIENT; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TOLERABILITY; HUMAN; NOTE; PRIORITY JOURNAL;

EID: 78049477444     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pain.2010.08.026     Document Type: Editorial

References (12)

1. P.H. Coluzzi, L. Schwartzberg, J.D. Conroy, S. Charapata, M. Gay, M.A. Busch, J. Chavez, J. Ashley, D. Lebo, M. McCracken, and R.K. Portenoy Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC®) and morphine sulphate immediate release (MSIR®) Pain 91 2001 123 130
2. L.L. Christrup, D. Foster, L.D. Popper, T. Troen, and R. Upton Pharmacokinetics, efficacy, and tolerability od fentanyl following intranasal versus intravenous administration in adults undergoing third-molar extraction: A randomized, double-blind, double-dummy, two-way, cross-over study Clin Ther 30 2008 469 481
3. J.T. Farrar, J. Cleary, R. Rauck, M. Busch, and E. Nordbrock Oral transmucosal fentanyl citrate (OTFC): Randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients J Natl Cancer Inst 90 1998 611 616
4. S.J. Farr, and B.A. Otulana Pulmonary delivery of opioids as pain therapeutics Adv Drug Deliv Rev 58 2006 1076 1088
5. A.P. Jekunen, C. Cotterill-Jones, P. Dewlan, T. Tanner, H. Sikorska, L. Asking, and T. Jouhikainen Dose linearity of inhaled fentanyl with comparative pharmacokinetics to transmucosal fentanyl J Clin Oncol (2006 ASCO Annual Meeting Proceedings Part I) 24 2006 8629
6. N. Katz Enriched enrollment randomized withdrawal trial designs of analgesics. Focus on methodology Clin J Pain 25 2009 797 807
7. H.G. Kress, A. Orońska, Z. Kaczmarek, S. Kaasa, T. Colberg, and T. Nolte Efficacy and tolerability of intranasal fentanyl spray 50 to 200μg for breakthrough pain in patients with cancer: A phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with 10-month, open-label extension treatment period Clin Ther 31 2009 1177 1191
8. S. Mercadante, L. Radbruch, A. Davies, P. Poulain, T. Sitte, P. Perkins, T. Colberg, and M.A. Camba A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: and open-label, randomised, crossover trial Curr Med Opin Res 25 2009 2805 2815
9. K. Moksnes, O.M. Fredheim, P. Klepstad, S. Kaasa, A. Angelsen, T. Nilsen, and O. Dale Early pharmacokinetics of nasal fentanyl: is there a significant arterio-venous difference? Eur J Clin Pharmacol 64 2008 497 502
10. Portenoy R, Burton AW, Gabrail N, Taylor D, on behalf of the fentanyl Pectin Nasal Spray 043 group. A multicenter, placebo-controlled, double-blind, multiple-crossover study of fentanyl pectin nasal spray (FPNS) in the treatment of breakthrough cancer pain. Pain 2010;151:617-24.
11. R.K. Portenoy, D. Payne, and P. Jacobsen Breakthrough pain: characteristics and impact in patients with cancer pain Pain 81 1999 129 134
12. R.K. Portenoy, D. Taylor, J. Messina, and L. Tremmel A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer Clin J Pain 22 2006 805 811